TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22166525
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 30 mg/30 ml, 29 doses over 24 months
Study: 22166525
Drug: Pirarubicin (THP)
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin (THP) 30 mg/30 ml, 29 doses over 24 months
Study: 8349477
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg)
Study: 31493397
Drug: Subcutaneous mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous mirikizumab 200 mg every 12 weeks
Study: 26084944
Drug: Intraocular lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular lens treatment
Study: 21955403
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg/day plus rosiglitazone 4 mg/day
Study: 21955403
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg/day plus placebo
Study: 17125998
Drug: Sufentanil 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.75 microg/mL with bupivacaine
Study: 17125998
Drug: Sufentanil 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.75 microg/mL with ropivacaine
Study: 9797234
Drug: Piperacillin-tazobactam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (4.5 g three times a day)
Study: 9797234
Drug: Imipenem-cilastatin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (0.5 g four times a day)
Study: 8457237
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate (MPA) 0.01%, 0.05%, 0.1%, 0.5% ointment
Study: 8457237
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate (MPA) 0.1% (cream, ointment, fatty ointment)
Study: 8457237
Drug: Difluocortolone 21-valerate
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difluocortolone 21-valerate 0.1% (DFV) ointment
Study: 31372210
Drug: Conventional Endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Endodontic Treatment (Endo)
Study: 25179753
Drug: Screening, Assessment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening, Assessment, and Referral to Treatment (SAR)
Study: 20041428
Drug: Pycnogenol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (oral and topical)
Study: 12412822
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray
Study: 12222660
Drug: PYCNOGENOL chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PYCNOGENOL chewing gums (5 mg)
Study: 10381531
Drug: SCF +
Normalized name: Immunoglobulin scfv-scfv-scfc, anti-(homo sapiens dll3 (delta-like ligand 3)) and anti-(homo sapiens cd3e (cd3 epsilon, leu-4)), monoclonal antibody single chain (scfv)2-scfc, bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCF + G-CSF
Study: 10381531
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + SCF
Study: 30701655
Drug: Treatment stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment stimulation (peripheral nerve stimulation)
Study: 28210811
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health care training (IG)
Study: 9779099
Drug: Etched (phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etched (phosphoric acid gel)
Study: 2698272
Drug: Amineptine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amineptine (100-200 mg per day)
Study: 2698272
Drug: Imipramine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50-100 mg per day)
Study: 31084971
Drug: Intraoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ketamine infusion at a rate of 6 mcg/kg/min for 75 minutes
Study: 31084971
Drug: Intraoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ketamine infusion
Study: 27823944
Drug: Cervical lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical lidocaine-prilocaine (LP) cream
Study: 26123101
Drug: Bovine milk
Normalized name: Bovine Milk Plasma
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk containing antibodies
Study: 23731768
Drug: AZD3199 (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3199 (200, 400 or 800 μg o.d.)
Study: 23731768
Drug: Formoterol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (9 μg b.i.d.)
Study: 19268410
Drug: Cyclosporine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (5 to 6 mg/kg/d)
Study: 9477980
Drug: Deferral of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferral of photocoagulation in eyes assigned to the Early Treatment Diabetic Retinopathy Study (ETDRS)
Study: 3673206
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram of Pasteur's hepatitis B vaccine
Study: 27369430
Drug: Amoxicillin (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (first taste)
Study: 27369430
Drug: Amoxicillin (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (second taste)
Study: 27369430
Drug: Acetaminophen elixir
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen elixir
Study: 11826230
Drug: Acetaminophen suspension
Normalized name: PediaCare Children's Flu Plus Acetaminophen Suspension (Bubble Gum)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen suspension
Study: 26273191
Drug: Torasemide-PR 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide-PR 10 mg
Study: 26273191
Drug: Furosemide-IR 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide-IR 40 mg
Study: 21669380
Drug: Loss of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loss of 2 g/dl Hgb or more
Study: 19358959
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus adjunctive care by a homeopath
Study: 12740264
Drug: Budesonide/formoterol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (80 micro g/4.5 micro g, bid)
Study: 12740264
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micro g, bid)
Study: 9179687
Drug: Preoperative endocrine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative endocrine therapy (leuprolide and chlormadinone for 3 months)
Study: 3972658
Drug: 252Cf implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 252Cf implants alone (Group I)
Study: 17631387
Drug: Diaphragm, lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm, lubricant gel, and condoms
Study: 1570380
Drug: Triazolam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.50 mg
Study: 3413202
Drug: Zolpidem 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 20 mg
Study: 2514430
Drug: Taprostene (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taprostene (25 ng/kg/min intravenously for 6 hours daily on 5 consecutive days)
Study: 126075
Drug: 0.1% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hydrocortisone cream with vasoconstrictor activity
Study: 126075
Drug: 1.0% Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% Hydrocortisone Cream BPC
Study: 31913519
Drug: ubrogepant 50
Normalized name: ubrogepant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ubrogepant 50 mg
Study: 23750422
Drug: Special effect
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special effect San Xiao decoction (1 dose/d for 12 weeks)
Study: 23750422
Drug: Metformin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (0.5 g/time, oral, 2 times/d)
Study: 16872965
Drug: Conventional technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional technique (veins stripped, distended, stored in saline solution)
Study: 12611783
Drug: BCAA (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (60 g)
Study: 10383522
Drug: OMC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 250 mg b.d.)
Study: 9122729
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant interferon alfa-2b (rIFN‐alpha 2b)
Study: 17646228
Drug: IV prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV prednisolone, 60 mg for 5 days
Study: 17646228
Drug: Oral prednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone, 60 mg for 5 days
Study: 10691224
Drug: 3‐ml lidocaine‐epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐ml lidocaine‐epinephrine test dose + 12 ml bupivacaine, 0.0625%
Study: 10691224
Drug: 3‐ml lidocaine‐epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐ml lidocaine‐epinephrine test dose + 12 ml bupivacaine, 0.125%
Study: 27980409
Drug: Vilazodone 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 20-40 mg/d
Study: 20189517
Drug: Argon plasma
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon plasma coagulation (APC) in addition to biofeedback therapy (BT)
Study: 20189517
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care only (biofeedback therapy [BT])
Study: 8814688
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin and etoposide (EP) combined with cranial and local radiotherapy
Study: 8814688
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with vincristine, doxorubicin and cyclophosphamide (VAC)
Study: 8814688
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with VAC
Study: 8877887
Drug: Multidose nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose nebulizer (200 x 15 microL doses of flunisolide, 250 micrograms)
Study: 8877887
Drug: Pressurized metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered dose inhaler (MDI, 250 micrograms of flunisolide)
Study: 1642345
Drug: Bupivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (20 ml, 0.25%)
Study: 8311214
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine and bupivacaine
Study: 6134535
Drug: Pancuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.08 mg kg‐1
Study: 6134535
Drug: Vecuronium 0.057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.057 mg kg‐1
Study: 23486618
Drug: Ultrasound-guided (US)
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided (US) facet joint injections
Study: 16698524
Drug: Standard skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard skin medication (placebo; control group)
Study: 31077671
Drug: Diclofenac patch
Normalized name: diclofenac Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac patch
Study: 9495784
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy only (Control group)
Study: 12163429
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (placebo)
Study: 12166709
Drug: Conical crown-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conical crown-retained dentures (CC)
Study: 10597783
Drug: 3TC/ZDV with
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3TC/ZDV with 1050 mg APV added at week 12
Study: 10597783
Drug: APV 900
Normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APV 900 mg with 3TC/ZDV
Study: 17325296
Drug: Powdered garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered garlic supplement
Study: 17325296
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract supplement
Study: 11788172
Drug: Garlic tablet
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic tablet (Garlet) 800mg/day
Study: 9547667
Drug: Cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive group treatment program (CT)
Study: 7979426
Drug: One-shot group
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-shot group (one-shot arterial infusion chemotherapy)
Study: 7979426
Drug: RV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV group (arterial infusion chemotherapy through implantable port)
Study: 3052974
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone acetate
Study: 18447941
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of sugar cane policosanols (SCP)
Study: 17192538
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus capecitabine (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter on days 1 through 14 of a 21-day cycle)
Study: 17192538
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle)
Study: 10914847
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg hydroxychloroquine sulfate daily (Group B)
Study: 10914847
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg hydroxychloroquine sulfate daily (Group A)
Study: 8980924
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 50 mg of amitriptyline (AT) daily for 6 weeks
Study: 8980924
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 25 mg of amitriptyline (AT) daily for 6 weeks
Study: 1419760
Drug: Oral 8-methoxypsoralen
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 8-methoxypsoralen (oral 8-MOP)
Study: 24293632
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus, followed by continuous infusion of 100 mg/h for patients >70 kg or 70 mg/h for patients <70 kg over 48 h)
Study: 22520143
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (PRV)
Study: 11874743
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular hypotensive medication
Study: 16228196
Drug: Ketamine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (bolus of 0.23 mg/kg and infusion of 0.65 mg/kg)
Study: 15203290
Drug: Ethanol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.6 g/kg)
Study: 2707917
Drug: Ibopamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (100 mg, three times a day)
Study: 30669717
Drug: Jinghuaweikang capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinghuaweikang capsules (160 mg, three times a day) + Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Study: 30669717
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (esomeprazole 20 mg, twice a day; pectin bismuth 200 mg, three times a day; amoxicillin 1000 mg, twice a day; clarithromycin 500 mg, twice a day)
Study: 30669717
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Study: 29596646
Drug: OBMT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBMT therapy (bismuth, metronidazole, tetracycline with omeprazole)
Study: 29596646
Drug: OBAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBAC therapy (bismuth, omeprazole, amoxicillin, and clarithromycin)
Study: 29596646
Drug: Both OBMT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both OBMT and OBAC therapies
Study: 26498268
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioral Therapy (CBT) for 11 weeks
Study: 23262475
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered according to the same schedule as the treatment group
Study: 21055665
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 10 months
Study: 16302041
Drug: Amodiaquine Monotherapy
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine Monotherapy (AQ)
Study: 8515822
Drug: Scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.4 mg s.c.)
Study: 31468714
Drug: Revefenacin 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 700 µg
Study: 30668840
Drug: L-glutamic acid
Normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-glutamic acid inclusion levels: 2.88%
Study: 30668840
Drug: L-glutamic acid
Normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-glutamic acid inclusion levels: 3.08%
Study: 30668840
Drug: L-glutamic acid
Normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-glutamic acid inclusion levels: 2.68%
Study: 26312445
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections with ropivacaine (100 mg) and ketorolac (15 mg)
Study: 10209831
Drug: Shock energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock energy programmed at twice DFT+
Study: 7796255
Drug: long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: long term therapy
Study: 30021811
Drug: Higher cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cord blood 25OHD at birth (>31 ng/mL)
Study: 30021811
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood 25OHD levels >31 ng/mL
Study: 25850540
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - placebo vibratory stimulation (sham treatment).
Study: 21899766
Drug: One-page ADR
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-page ADR information letters administered at three occasions during 2008 to all physicians and nurses in the intervention units
Study: 16799399
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg daily and fenofibrate 160 mg daily (PPAR group)
Study: 14709198
Drug: Intensive subcutaneous
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive subcutaneous insulin therapy (ISIT)
Study: 1531044
Drug: Ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.15 mg/kg intravenous dose
Study: 6435483
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl injection
Study: 6435483
Drug: Intramuscular fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular fentanyl injection
Study: 14725783
Drug: Computer‐assisted multimedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer‐assisted multimedia training course for intravenous injection
Study: 8996137
Drug: L‐PAM alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PAM alone (10 mg/m2, 15 mg/m2, 17.5 mg/m2, 20 mg/m2)
Study: 8996137
Drug: L‐PAM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PAM plus WBH (at various doses)
Study: 20496730
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Xuanzhong (GB 39) combined with Chinese herbs pyrogenic dressing therapy
Study: 10735900
Drug: G‐CSF (lenogastrim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (lenogastrim) administered after chemotherapy
Study: 10735900
Drug: G‐CSF (lenogastrim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (lenogastrim) vs non-G‐CSF group
Study: 8823852
Drug: SmithKline Beecham
Approvals — FDA: no, EMA: no, PMDA: no
Description: SmithKline Beecham vaccine (Engerix‐B, 10 micrograms/dose)
Study: 30825395
Drug: Low-frequency intervention
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency intervention (monthly SMS for 6 months)
Study: 30423575
Drug: Naloxone (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.6 mg or 3.2 mg q70 kg IV)
Study: 2862514
Drug: Paracervical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical injection of vasopressin
Study: 29608680
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion (4 hours) of piperacillin-tazobactam or ceftazidime